

Advancing Care in HFmrEF/HFpEF: Optimizing Therapies for Better Outcomes

TOPIC SUMMARY

Heart Failure with preserved ejection fraction (HFpEF) is a diverse syndrome often driven by conditions like hypertension, diabetes, obesity, and coronary or kidney disease. It is defined as heart failure with a LVEF (left ventricular ejection fraction) is $\geq 50\%$ and accounting for more than 50% of all patients with heart failure. HFmrEF (mildly reduced ejection fraction) is diagnosed in patients with HF symptoms and LVEF between 41–49%.

LEARNING OBJECTIVES

After completing this activity, participants should better be able to:

- Recognize and discuss the high unmet clinical and societal burden of HFmrEF/HFpEF.
- Describe the importance of early initiation of proven treatment options to improve health outcomes and reduce residual risk for patients at risk for HF and with HF.
- Differentiate between non-steroidal MRAs and steroidal MRAs as treatment options for HFmrEF/HFpEF including mechanism of action, efficacy, and safety.

DISCLOSURE STATEMENTS

The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

PLANNING COMMITTEE (PC)/FACULTY DISCLOSURE STATEMENTS

PC/ Faculty Member	Employment	Researcher	Contract/Grant, Independent Contractor (including contracted research)	Consultant/Advisory Board	Royalties or patent beneficiary, executive role, ownership interest	Stock/stock options	Speaker/Other
Celeste Chavez, RN, MSN, FNP-BC	Sutter Health	N/A	N/A	N/A	N/A	N/A	N/A

Meg Fraser, DNP, ANP-C, FHFA, CHFN	University of Minnesota	N/A	N/A	Heart Failure Society of America, University of Colorado	N/A	N/A	N/A
Orly Vardeny, PharmD, MS	University of Minnesota	N/A	AstraZeneca, Bayer, Cardurion, Duke Clinical Research Institute, Food and Drug Administration, Sanofi Pasteur Biologics, LLC	Cardior, Cytokinetics, Novo Nordisk	N/A	N/A	N/A
Anita Deswal, MD, MPH	University of Texas MD Anderson Cancer Center	N/A	N/A	Bayer, Colorado Prevention Center Clinical Research	N/A	N/A	N/A
Sabra C. Lewsey, MD, MPH, FACC, FHFA	Johns Hopkins University SOM	N/A	National Institute of Health, Winn Career Development Award	N/A	N/A	N/A	Assoc. of Black Cardiologists (board member), Heart Failure Society of America (scientific statements committee, member)
Alvin Washington, MD	CSW Medical Writing, LLC	N/A	N/A	N/A	N/A	N/A	N/A

TARGET AUDIENCE

- Cardiologists
- Primary Care/Family Medicine Physicians
- Physicians
- Physician Assistants
- Nurse Practitioners
- Nurses
- Pharmacists
- Other Health Care Professionals involved in the care of patients with heart failure

SUCCESSFUL COMPLETION OF ACTIVITY

Each attendee must successfully complete the following steps:

1. Attend the presentation.
2. Complete the Attendance Verification Form and return to the site coordinator.
3. Complete the online Evaluation Survey
4. Claim your Certificate of Attendance

The site coordinator will hand out instructions on completing the online Evaluation Survey and Claiming your Certificate of Attendance.

IMPORTANT CONTACT INFORMATION

For technical questions, please contact the AHA Customer Service.

- Telephone: 877-340-9899
- Email: education.help@email.education.heart.org

For program questions email: AHASpotlightSeries@heart.org

This program is sponsored by Bayer. Content has been created and directed by a volunteer planning committee.